Memorial Sloan Kettering Cancer Center (MSK) recently appointed Sergio Giralt, MD, and Miguel-Angel Perales, MD, as Deputy Division Head of the Division of Hematologic Malignancies and Chief of the Adult Bone Marrow Transplant Service, respectively.
Sergio Giralt, MD
Miguel-Angel Perales, MD
Dr. Giralt: New Roles and Old
Former Chief of the Adult Bone Marrow Transplant Service, Dr. Giralt is the Melvin Berlin Family Chair in Multiple Myeloma. Since joining MSK in May 2010, Dr. Giralt has contributed to the field of bone marrow transplantation through the development of the use of reduced-intensity conditioning regimens for older or debilitated patients with blood cancers.
In his new role, Dr. Giralt will oversee and coordinate the activities of transplant and cellular therapy in MSK’s Department of Medicine and other departments, foster collaborations between members of the division, and develop a joint research program for stem cell transplant and cellular therapies.
Dr. Giralt earned his medical degree from the Universidad Central de Venezuela, completed his residency in internal medicine at Good Samaritan Hospital, and followed it with a fellowship in Medical Oncology at MD Anderson Cancer Center. His clinical and research focus is on improving stem cell transplantation treatments for older patients who have acute and chronic leukemias.
Dr. Perales: Experience and Education
Dr. Perales, former Deputy Chief of the Adult Bone Marrow Transplant (BMT) Service and Director of the Adult BMT Fellowship Program, was appointed Chief of the Adult BMT Service. At MSK, Dr. Perales has been responsible for directing studies and monitoring the immune systems of people undergoing stem cell transplantation.
In his new role, Dr. Perales will help with ongoing efforts to expand the development of the Adult BMT Service and its clinical, research, and educational programs.
After receiving his medical degree from the Free University of Brussels, Dr. Perales completed fellowships in medical oncology/hematology at MSK and in medicine at Weill Cornell Medical College as well as a residency in internal medicine at the Tufts-New England Medical Center. He is currently leading clinical trials to evaluate chemotherapy regimens to improve outcomes in patients with diffuse large B-cell lymphoma and to treat acute graft-vs-host disease.
